From Licensing to Acquisition: End-to-End CMC Enablement for a Clinical-Stage Biotech

The client was effectively starting CMC operations from zero while the clinical clock was already ticking. Any gap in functional coverage risked supply interruption, a missed regulatory deadline, or a critical CMC finding, all of which would severely erode the company’s valuation during future transaction discussions.

The critical complexities include:

• Immediate Tech Transfer and Infrastructure Setup: Absorbing a complete technical and documentation transfer from the licensor without stalling ongoing trials, while simultaneously engaging a new CDMO network for Drug Substance manufacturing, Drug Product fill/finish, analytical testing, and global clinical trial material (CTM) storage and supply.
• Aggressive Global Regulatory Cadence: Authoring and submitting IND Module 3 content, IMPDs, amendments, and Health Authority responses on a rolling basis across multiple regions, alongside preparing for pivotal Type B regulatory meetings.
• Diligent Quality Compliance: Building a phase-appropriate Quality Management System (QMS) from scratch and maintaining strict CDMO quality oversight to ensure the assets and data would withstand intense scrutiny during eventual buyer due diligence.

Hiring 5 to 6 full-time, senior CMC leaders to cover this multi-disciplinary scope was neither financially viable nor fast enough for the client’s aggressive timeline.

Syner-G deployed a fractional, fully integrated CMC operating model that completely bypassed the need for an internal buildout. A single Syner-G CMC program director, backed by a strategic advisor and senior subject matter experts (SMEs) across Drug Substance, Drug Product, Analytical Development, Supply Chain, Regulatory CMC, and Quality Assurance, was embedded into the client’s operation from day one. Because every functional lead brought more than 20 years of specialized industry experience, the team delivered immediate productivity.

Agile Resource Scaling: The engagement was precisely sized to the actual technical workload rather than an arbitrary headcount plan. Part-time senior SME hours flexed up and down dynamically based on active project milestones, delivering the functional breadth of a large pharma development team at a fraction of the cost. As the program matured and workload increased, execution-level resources were layered in seamlessly underneath the leads. This preserved operational continuity through the onboarding of the client’s first two internal CMC hires and, ultimately, through the complete acquisition transition.

Full-Spectrum CMC & Quality Ownership: Across the nearly three-year engagement, Syner-G owned the entire breadth of the CMC enterprise:

• Strategic Planning: Leading end-to-end CMC program management and phaseappropriate development planning to bridge Phase 2 data into Phase 3 readiness.
• Supply Chain & Vendor Management: Executing technical due diligence and a comprehensive documentation transfer from the licensor; managing the global CDMO network; and negotiating Master Service, Supply, and Quality Agreements.
• Operations & Quality Control: Overseeing investigational product manufacturing, clinical batch release, and analytical testing, while building out a phase-appropriate QMS to ensure total audit readiness.
• Regulatory & Knowledge Transfer: Authoring all global regulatory submissions (IND Module 3, IMPDs, and amendments), driving Type B meeting preparations, and executing a structured, meticulous knowledge transfer to the acquiring sponsor